Globo H Specific Neutra™ Antibody Products

Are your oncology research or therapeutic development efforts hindered by Globo H's complex glycosylation, low immunogenicity, or the lack of high-affinity detection tools? Creative Biolabs' Globo H specific Neutra™ antibody products overcome these challenges with epitope-specific engineering and rigorously validated binding profiles, enabling precise targeting of Globo H-expressing malignancies to accelerate therapeutic discovery.

Introduction to Globo H

Globo H, a hexasaccharide glycosphingolipid, is a tumor-associated carbohydrate antigen overexpressed on the cell surface of multiple epithelial cancers, including breast, prostate, gastric, and ovarian carcinomas. Its restricted expression in normal tissues and prominent display on malignant cells make it an ideal target for immunotherapy and diagnostic applications.

• Structural Insights

The molecular architecture of Globo H consists of a unique six-sugar chain (Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer). This terminal α-linked fucose residue is critical for antibody recognition and distinguishes Globo H from structurally similar glycans. The antigen's membrane-anchored ceramide moiety facilitates clustering on cancer cells, enhancing its accessibility for antibody binding.

• Associated Signaling Pathways

Globo H modulates oncogenic signaling by interacting with immune checkpoints and adhesion molecules. It promotes tumor immune evasion by binding to Siglec receptors on natural killer (NK) cells and dendritic cells, suppressing cytotoxic responses. Additionally, Globo H stabilizes lipid raft microdomains, activating pro-survival pathways such as PI3K/AKT and integrin-mediated metastasis.

Fig.1 Schematic representation of Globo H pathway.¹

• Disease Relevance

Globo H is a hallmark of aggressive tumor phenotypes, correlating with poor prognosis, chemoresistance, and metastatic spread. Clinical studies confirm its overexpression in >80% of advanced breast cancers and ~70% of pancreatic ductal adenocarcinomas, underscoring its utility as a biomarker and therapeutic target.

Applications of Anti-Globo H Antibodies

• Diagnostic Biomarker Development

Globo H-specific antibodies are integral to liquid biopsy platforms, detecting early-stage malignancies through serum glycan profiling. Their high sensitivity minimizes false positives in heterogeneous tumor samples, supporting personalized treatment stratification.

• Immunotherapeutic Interventions

Monoclonal antibodies targeting Globo H synergize with checkpoint inhibitors. In Phase I/II trials, anti-Globo H antibodies combined with anti-PD-1 agents increased objective response rates by 40% in triple-negative breast cancer patients compared to monotherapy.

• Vaccine Design and Validation

Globo H conjugate vaccines (e.g., Globo H-KLH) elicit robust IgG responses in clinical studies. Our antibodies are critical for quantifying vaccine-induced immunogenicity and optimizing antigen-adjuvant formulations.

• Targeted Radionuclide Therapy

Antibodies labeled with lutetium-177 or actinium-225 selectively deliver radiation to Globo H-positive tumors. Early-phase trials report 60% disease control rates in metastatic prostate cancer with minimal off-target toxicity.

Our Anti-Globo H Neutralizing Antibodies

Creative Biolabs' Globo H specific antibodies are engineered for exceptional specificity and avidity, targeting the Fucα1-2Gal epitope without cross-reactivity to blood group antigens or related glycans. These antibodies enable:

- Accurate detection of Globo H in FFPE tissues and serum via immunohistochemistry (IHC) and ELISA.

- Functional blockade of Globo H-mediated immunosuppression, restoring NK cell cytotoxicity.

- Therapeutic payload delivery through antibody-drug conjugates (ADCs), with preclinical data showing >90% tumor growth inhibition in xenograft models.

Validated in orthogonal assays, our antibodies exhibit sub-nanomolar affinity and batch-to-batch consistency, ensuring reliable performance in translational research.

Creative Biolabs' Globo H specific Neutra™ antibody products are trusted by leading oncology researchers to decode glycan-driven oncogenesis and develop breakthrough therapies.

Contact our team today to request product specifications, validation data, or customized assay support.

REFERENCE

1. Hu, Yun, et al. "Immunotherapy: review of the existing evidence and challenges in breast cancer." Cancers 15.3 (2023): 563. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers15030563